The drug SI-B001 shows a exciting development in the care of refractory multiple myeloma. This innovative antibody specifically binds to BCMA of myeloma cells, triggering antibody-dependent cell cytotoxicity while promoting anti-tumor immune activity. Early investigational results indicate substa